KR880005935A - 폴리펩타이드 성장 인자를 함유하는 안정화된 조성물 - Google Patents

폴리펩타이드 성장 인자를 함유하는 안정화된 조성물 Download PDF

Info

Publication number
KR880005935A
KR880005935A KR870012349A KR870012349A KR880005935A KR 880005935 A KR880005935 A KR 880005935A KR 870012349 A KR870012349 A KR 870012349A KR 870012349 A KR870012349 A KR 870012349A KR 880005935 A KR880005935 A KR 880005935A
Authority
KR
South Korea
Prior art keywords
growth factor
composition
milk substitute
epidermal growth
cellulose
Prior art date
Application number
KR870012349A
Other languages
English (en)
Inventor
엘.핀 케나우얼 아미
Original Assignee
로버트 엘.미니어
에티콘 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/927,627 external-priority patent/US4717717A/en
Application filed by 로버트 엘.미니어, 에티콘 인코포레이티드 filed Critical 로버트 엘.미니어
Publication of KR880005935A publication Critical patent/KR880005935A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
    • A23C9/206—Colostrum; Human milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
    • A61L17/005—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters containing a biologically active substance, e.g. a medicament or a biocide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
    • A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Materials Engineering (AREA)
  • Surgery (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Vascular Medicine (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Dairy Products (AREA)

Abstract

내용 없음

Description

폴리펩타이드 성장 인자를 함유하는 안정화된 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (41)

  1. 인체 유사 분열 환성을 갖는 폴리펩타이드 성장 인자 및 생물학적 활성의 손실에 대해서 성장 인자를 안정화 시키는데 충분한 양의 수용성 폴리삭카라이드를 함유하는 수성 약제 조성물.
  2. 제1항에 있어서, 성장 인자가 표피 성장 인자, 전환 성장 인자-알파, 전환 성장 인자-베타, 염기성 섬유 아세포 성장 인자, 산성 섬유아세포 성장 인자, 안지오게닌, 신경 성장 인자, 인슐린-유사 성장 인자, 혈소판-유도된 성장 인자 또는 그의 혼합물로 이루어진 그룹으로부터 선택되는 조성물.
  3. 제1항에 있어서, 성장 인자가 표피 성장 인자인 조성물.
  4. 제1항에 있어서, 폴리삭카라이드가 셀룰로오즈 유도체인 조성물.
  5. 제4항에 있어서, 셀룰로오즈 유도체가 하이드록시 프로필 셀룰로오즈, 메틸셀룰로오즈, 하이드록시에틸 셀룰로오즈, 하이드록시프로필 메틸셀룰로오즈 또는 그의 혼합물인 조성물.
  6. 제3항에 있어서, 표피 성장 인자가 인체 표피 성장 인자인 조성물.
  7. 활성 성분으로서 유사 분열 환성을 갖는 폴리 펩타이드 성장 인자를 함유하는 수성 약제 조성물에, 물의 존재하에서 생물학적 활성의 손실에 대해 성장 인자를 안정화 시키기에 충분한 양의 수용성 폴리삭카라이드를 혼입시킴을 특징으로 하여, 폴리펩타이드 성장 인자를 함유하는 수성 약제 조성물을 안정화시키는 방법.
  8. 제7항에 있어서. 성장 인자가 표피 성장 인자, 전환 성장 인자-알파, 전환 성장 인자-베타, 염기성 섬유 아세포 성장 인자, 산성 섬유아세포 성장 인자, 안지오게닌, 신경 성장 인자, 혈소판-유도된 성장 인자 또는 그의 흔합물로 이루어진 그룹으로부터 선택되는 방법.
  9. 제7항에 있어서, 성장 인자가 표피 성장 인자인 방법.
  10. 제7항에 있어서, 폴리삭카라이드가 셀룰로오즈 유도체인 방법.
  11. 제10항에 있어서, 셀룰로오즈 유도체가 하이드록시프로필 셀룰로오즈, 하이드록시에틸 셀룰로오즈, 메틸셀룰로오즈, 하이드록시프로필 메틸셀룰로오즈 또는 그의 혼합물인 방법.
  12. 제9항에 있어서, 표피 성장 인자가 인체 표피 성장 인자인 방법.
  13. a) 약 1 내지 약 1000㎍/㎖의 표피 성장 인자(EGF); 및 b) 점도를 1 내지 5000cps범위 내로 유지시키기 위한 안과용으로 적합한 수용성 중합체를 함유하는 안과용의 약제학적 조성물.
  14. 제13항에 있어서, 중합체가 약 0.05% 내지 약 3.0%(W/V)의 농도로 존재하는 조성물.
  15. 제13항에 있어서, EGF 농도가 약 10 내지 약 500㎍/㎖인 조성물.
  16. 제13항에 있어서, 중합체가 폴리삭카라이드, 비닐폴리머, 폴리아미노산, 폴리에틸렌 글리콜 및 히알루론 산으로 구성된 그룹으로부터 선택되는 조성물.
  17. 제16항에 있어서, 폴리삭카라이드가 셀룰로오즈 유도체인 조성물.
  18. 제16항에 있어서, 비닐 폴리머가 폴리비닐 알콜 또는 폴리비닐 피롤리돈인 조성물.
  19. 제13항에 있어서, 추가로 보존재를 함유하는 조성물.
  20. 제19항에 있어서 보존제의 농도가 약 0.0002% 내지 약 2.5%(W/V)인 조성물.
  21. 제19항에 있어서, 보존제가 치메로살, 소르브산, 클로로부탄올, EDTA 및 파라벤으로 구성된 그룹으로부터 선택되는 조성물.
  22. 제13항에 있어서, 추가로 등장성화제를 함유하는 조성물.
  23. 제22항에 있어서, 등장성화제 농도가 약 1.8%(W/V)이하인 조성물.
  24. 제22항에 있어서, 등장성화제가 클로라이드 염인 조성물.
  25. 제13항에 있어서, pH를 약 5.0 내지 약 8.0 사이로 유지하기 위한 완충제를 추가로 함유하는 조성물.
  26. 제25항에 있어서, 완충제가 포스페이드 완충제, 시트레이트 완충제, 보레이트 완충제 및 아세테이트 완충제로 구성된 그룹으로부터 선택되는 조성물.
  27. 환부 치료 유효량의 제13항의 조성물을 환부에 접촉시킴을 특징으로 하여 환부 눈의 환두 치료 속도를 증가시키는 방법.
  28. 제27항에 있어서, 환부가 각막상의 환부인 방법.
  29. 제1항의 조성물을 함유하는 약제학적으로 적합한 크림.
  30. 제1항의 조성물을 함유하는 약제학적으로 적합한 겔.
  31. 제1항의 조성물로 피복 또는 적셔진 봉합실.
  32. 제1항의 조성물로 적셔진 흡수 거즈 드레싱.
  33. a) 제1항의 조성물로 흡수 거즈 드레싱을 적시고; b) 적셔진 거즈를 환부에 부착시킴을 특징으로 하여 환부의 치료 속도를 증가시키는 방법.
  34. 환부에 제1항의 조성물을 접촉시킴을 특징으로 하여, 환부의 치료속도를 증가시키는 방법.
  35. 제1항의 조성물을 함유하는 모유 대용품.
  36. 재조합 인체 EGF 및 사람의 영양에 필수적인 아미노산을 제공할 수 있는 영양학적 양의 단백질을 함유한 모유 대용품.
  37. 제36항에 있어서, 단백질이 우유로부터 유도된 모유 대용품.
  38. 제36항에 있어서, 단백질이 대두로부터 유도된 모유 대용품.
  39. 제36항에 있어서, 추가로 영양학적 양의 탄수화물을 함유하는 모유 대용품.
  40. 동결 건조 분말화된 제35항의 모유 대용품.
  41. 동결건조된 제36항의 모유 대용품.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR870012349A 1986-11-05 1987-11-04 폴리펩타이드 성장 인자를 함유하는 안정화된 조성물 KR880005935A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US927627 1986-11-05
US06/927,627 US4717717A (en) 1986-11-05 1986-11-05 Stabilized compositions containing epidermal growth factor
US9645587A 1987-09-18 1987-09-18
US96455 1987-09-18

Publications (1)

Publication Number Publication Date
KR880005935A true KR880005935A (ko) 1988-07-21

Family

ID=26791728

Family Applications (1)

Application Number Title Priority Date Filing Date
KR870012349A KR880005935A (ko) 1986-11-05 1987-11-04 폴리펩타이드 성장 인자를 함유하는 안정화된 조성물

Country Status (13)

Country Link
EP (1) EP0267015B1 (ko)
JP (2) JP2942227B2 (ko)
KR (1) KR880005935A (ko)
AU (1) AU614941B2 (ko)
CA (1) CA1322328C (ko)
DE (1) DE3781509T2 (ko)
DK (1) DK579787A (ko)
ES (1) ES2044952T3 (ko)
GR (1) GR871700B (ko)
MX (1) MX171861B (ko)
NZ (2) NZ222413A (ko)
PT (1) PT86075B (ko)
SG (1) SG104292G (ko)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100366439B1 (ko) * 2000-02-21 2003-01-09 주식회사 대웅 상피세포 성장인자를 유효성분으로 하는 안정한 약제학적조성물
KR100426223B1 (ko) * 2000-10-27 2004-04-08 한건 수용성 펩타이드 약물의 건조 리포좀 조성물 및 그의 제조방법

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019559A (en) * 1986-11-14 1991-05-28 President And Fellows Of Harvard College Wound healing using PDGF and IGF-II
US5472702A (en) * 1987-08-26 1995-12-05 United States Surgical Corporation Sterilization of growth factors
US5366081A (en) 1987-08-26 1994-11-22 United States Surgical Corporation Packaged synthetic absorbable surgical elements
US5226912A (en) 1987-08-26 1993-07-13 United States Surgical Corporation Combined surgical needle-braided suture device
US5306289A (en) * 1987-08-26 1994-04-26 United States Surgical Corporation Braided suture of improved characteristics
US5222978A (en) 1987-08-26 1993-06-29 United States Surgical Corporation Packaged synthetic absorbable surgical elements
US5705485A (en) * 1987-09-18 1998-01-06 Ethicon, Inc. Gel formulations containing growth factors
US4983581A (en) * 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β
AU614137B2 (en) * 1988-06-06 1991-08-22 Takeda Chemical Industries Ltd. Stabilized fgf composition and production thereof
CA1330391C (en) * 1988-07-19 1994-06-28 Matthew E. Hermes Method for improving the storage stability of a polymeric article susceptible to hydrolic degradation and resulting article
US5034375A (en) * 1988-08-10 1991-07-23 Institute Of Molecular Biology, Inc. Process of wound healing using PDGF and EGF
GB8823649D0 (en) * 1988-10-07 1988-11-16 Geistlich Soehne Ag Chemical compounds
US5013714A (en) * 1988-12-15 1991-05-07 Lindstrom Richard L Viscoelastic solution
US5693625A (en) * 1989-03-09 1997-12-02 Therapeutiques Substitutives Method of regenerating cells and tissues using functionalized dextrans
FR2644066B1 (fr) * 1989-03-09 1994-05-13 Therapeutiques Substitutives Compositions stabilisees comprenant des fgfs, leur procede d'obtention et leurs applications therapeutiques, chirurgicales et cosmetologiques
CA2020654A1 (en) * 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
US5359831A (en) 1989-08-01 1994-11-01 United States Surgical Corporation Molded suture retainer
US5246104A (en) * 1989-08-01 1993-09-21 United States Surgical Corporation Molded suture retainer
US5422340A (en) * 1989-09-01 1995-06-06 Ammann; Arthur J. TGF-βformulation for inducing bone growth
IT1240683B (it) * 1990-04-26 1993-12-17 Zambon Spa Composizione farmaceutica contenente egf
EP0531425B1 (en) * 1990-05-30 2002-08-14 The President And Fellows Of Harvard College Combination of IGF-I and TGF-beta for bone regeneration
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
GB9014871D0 (en) * 1990-07-05 1990-08-22 Erba Carlo Spa Drug delivery system for administering growth factor
NZ234439A (en) * 1990-07-10 1997-08-22 Pharmacia & Upjohn Ab Use of igf-1 to reduce fetal growth retardation in non human mammals
US5714458A (en) * 1990-07-18 1998-02-03 Farmitalia Carlo Erba S.R.L. Stable pharmaceutical compositions containing a fibroblast growth factor
GB9015824D0 (en) * 1990-07-18 1990-09-05 Erba Carlo Spa Stable pharmaceutical compositions containing a fibroblast growth factor
CA2055811A1 (en) * 1991-01-11 1992-07-12 Ross R. Muth Sterilization of growth factors
CA2059245C (en) * 1991-02-08 2004-07-06 Michael P. Chesterfield Method and apparatus for calendering and coating/filling sutures
US5705178A (en) * 1991-05-31 1998-01-06 Gliatech, Inc. Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
AU3062392A (en) * 1991-11-04 1993-06-07 Novo Nordisk A/S Pdgf gel formulation
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
US5348941A (en) * 1992-04-01 1994-09-20 Merck & Co., Inc. Stabilizers for fibroblast growth factors
GB9210574D0 (en) * 1992-05-18 1992-07-01 Ca Nat Research Council Biotherapeutic cell-coated microspheres for wound/burn and prothesis implant applications
CA2104418A1 (en) * 1992-08-24 1994-02-25 Miguel A. Maestro Method of preparing hydrindane compounds and hydrindane-related compounds
CU22405A1 (es) * 1993-07-05 1996-01-31 Cigb Composicion cosmetica para el cuidado de la piel
US6277828B1 (en) 1993-08-20 2001-08-21 Syntex (U.S.A.) Inc. Pharmaceutical formulations of nerve growth factor
DE4438015A1 (de) * 1994-10-25 1996-05-02 Boehringer Mannheim Gmbh Epithelzellenhaltiges Biomaterial und dessen Verwendung als Transplantat
US5904716A (en) * 1995-04-26 1999-05-18 Gendler; El Method for reconstituting cartilage tissue using demineralized bone and product thereof
US6572820B2 (en) 1996-02-05 2003-06-03 Asahi Medical Co., Ltd. Sterilization-protecting agent and sterilization method
WO1997032572A2 (en) * 1996-03-04 1997-09-12 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
US6391296B1 (en) * 1997-08-01 2002-05-21 Toray Industries, Inc. Method of stabilizing useful protein and useful protein compositions
IT1298758B1 (it) * 1998-03-19 2000-02-02 Angelini Ricerche Spa Soluzione umettante e lubrificante per uso oftalmico
EP1808160A3 (en) 1998-10-05 2008-03-05 The Penn State Research Foundation Compositions and methods for enhancing receptor-mediated cellular internalization
GB2344519B (en) * 1998-12-07 2004-05-19 Johnson & Johnson Medical Ltd Sterile therapeutic compositions
US20030228288A1 (en) 1999-10-15 2003-12-11 Scarborough Nelson L. Volume maintaining osteoinductive/osteoconductive compositions
US6309454B1 (en) 2000-05-12 2001-10-30 Johnson & Johnson Medical Limited Freeze-dried composite materials and processes for the production thereof
US9387094B2 (en) 2000-07-19 2016-07-12 Warsaw Orthopedic, Inc. Osteoimplant and method of making same
US7323193B2 (en) 2001-12-14 2008-01-29 Osteotech, Inc. Method of making demineralized bone particles
NZ527916A (en) 2001-01-30 2006-10-27 Orthogene Inc Compositions and methods for the treatment and repair of defects or lesions in articular cartilage using synovial-derived tissue or cells
CA2456833A1 (en) * 2001-08-10 2003-02-20 Masahiro Inohara Polysaccharide-containing compositions and use thereof
US7163691B2 (en) * 2001-10-12 2007-01-16 Osteotech, Inc. Bone graft
KR20050042032A (ko) * 2001-11-02 2005-05-04 세키스이가가쿠 고교가부시키가이샤 사이토카인 유도 재료 및 사이토카인 유도 용구
US20030109820A1 (en) * 2001-12-07 2003-06-12 Gross T. Daniel Hemostatic agent delivery system
EP1638486A4 (en) 2003-06-11 2010-09-29 Osteotech Inc OSTEOIMPLANTATES AND METHOD FOR THE PRODUCTION THEREOF
EP1749018B1 (en) * 2004-04-23 2014-10-22 Expedeon Limited Methods and kits for stabilising, protecting and solubilising proteins
CA2612405A1 (en) 2005-06-17 2006-12-28 Regenerx Biopharmaceuticals, Inc. Lkktet and/or lkktnt compositions and methods for treating or preventing tissue deterioration, injury or damage
EP1921453A4 (en) * 2005-07-20 2008-12-31 Kyowa Medex Co Ltd PROCESS FOR STABILIZING PEPTIDE CONTAINED IN A BIOLOGICAL SAMPLE
WO2007056671A1 (en) 2005-11-02 2007-05-18 Osteotech, Inc. Hemostatic bone graft
KR100748390B1 (ko) * 2005-11-14 2007-08-10 주식회사 대웅 상피세포성장인자를 포함하는 상처치료용 서방성 필름 제형
KR100784134B1 (ko) 2006-10-09 2007-12-12 주식회사 대웅 상피세포성장인자를 함유하는 안정한 구내염 치료용 액상조성물
JP2008200195A (ja) * 2007-02-19 2008-09-04 Daitaro Fukuoka 形成施術用糸およびこれを用いた形成施術方法
US20090192554A1 (en) 2008-01-29 2009-07-30 Confluent Surgical, Inc. Bioabsorbable block copolymer
EP2358352B1 (en) 2008-10-24 2018-08-29 Warsaw Orthopedic, Inc. Compositions and methods for promoting bone formation
CN102389392B (zh) * 2011-11-02 2012-10-24 珠海亿胜生物制药有限公司 重组牛碱性成纤维细胞生长因子眼用凝胶
MX351881B (es) 2012-03-01 2017-11-01 Firststring Res Inc Geles tópicos que contienen péptidos de alfa-conexina c- terminal (act).
CN104740677B (zh) * 2015-04-23 2017-06-06 广西达庆生物科技股份有限公司 一种皮肤医用修复敷料及其制备方法
CN106720379A (zh) * 2016-12-05 2017-05-31 中国科学院兰州化学物理研究所 一种驼血多肽奶片及其制备方法
US11241480B2 (en) * 2017-01-26 2022-02-08 Washington University Methods for modulation of dietary and microbial exposure with compositions comprising an EGFR ligand
TWI777115B (zh) * 2018-12-28 2022-09-11 國立成功大學 穩定生長因子活性的製備方法
CN110075054A (zh) * 2019-06-06 2019-08-02 山东天源人乳库科技发展有限公司 一种来源于人乳的人源性生长因子修复制剂及其制备方法
US20230031385A1 (en) * 2021-07-20 2023-02-02 National Health Research Institutes Storage media for preservation of corneal tissue

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179497A (en) * 1973-12-17 1979-12-18 Merck & Co., Inc. Solid state ophthalmic medication
EP0140998B1 (en) * 1983-11-02 1989-11-15 Nihon Chemical Research Kabushiki Kaisha Ophthalmic preparations
JPS60258125A (ja) * 1984-06-06 1985-12-20 Hayashibara Biochem Lab Inc 蛋白性生理活性物質を含有する水溶性乾燥物
EP0193917A3 (en) * 1985-03-06 1987-09-23 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100366439B1 (ko) * 2000-02-21 2003-01-09 주식회사 대웅 상피세포 성장인자를 유효성분으로 하는 안정한 약제학적조성물
KR100426223B1 (ko) * 2000-10-27 2004-04-08 한건 수용성 펩타이드 약물의 건조 리포좀 조성물 및 그의 제조방법

Also Published As

Publication number Publication date
SG104292G (en) 1992-12-24
JP2988925B2 (ja) 1999-12-13
JPH10167980A (ja) 1998-06-23
NZ222413A (en) 1991-06-25
GR871700B (en) 1988-03-04
AU8064187A (en) 1988-05-12
EP0267015B1 (en) 1992-09-02
JPS63152324A (ja) 1988-06-24
MX171861B (es) 1993-11-22
DK579787D0 (da) 1987-11-04
JPH11255663A (ja) 1999-09-21
CA1322328C (en) 1993-09-21
EP0267015A2 (en) 1988-05-11
JP2942227B2 (ja) 1999-08-30
EP0267015A3 (en) 1990-01-17
ES2044952T3 (es) 1994-01-16
PT86075B (pt) 1990-11-07
DE3781509T2 (de) 1993-01-07
DK579787A (da) 1988-05-06
PT86075A (en) 1987-12-01
DE3781509D1 (de) 1992-10-08
AU614941B2 (en) 1991-09-19
NZ235556A (en) 1991-06-25

Similar Documents

Publication Publication Date Title
KR880005935A (ko) 폴리펩타이드 성장 인자를 함유하는 안정화된 조성물
EP0859596B1 (en) Gel formulations containing growth factors
EP1206271B1 (en) Composition and method for enhancing wound healing
US4725576A (en) Fungicidal polypeptide compositions containing L-histidine and methods for use therefore
US8247373B2 (en) Lactoferrin compositions and methods of wound treatment
NO170194C (no) Fremgangsmaate for fremstilling av fysiologisk aktive saarhelingsstoffer
KR870000924A (ko) 성장 호르몬 투여용 조절방출삽입자의 제조방법
Neal et al. Inhibition of neutrophil degranulation and superoxide production by sulfasalazine: Comparison with 5-aminosalicylic acid, sulfapyridine and olsalazine
US5238925A (en) Angiogenic factor isolated from live yeast cell derivatives and its use in treating wounds or burns in mammals
GB2052979A (en) Ophthalmological use for colostrum
AU5916990A (en) Preparations for topical use containing depolymerized deoxyribonucleic acids to reduce unsightly defects of the epidermis of the face and some skin areas of the body
CA2314899A1 (en) Compositions and methods for regulating phagocytosis and icam-1 expression
EP1108429A3 (en) An improved amino acid composition for providing an amino acid supplement or protein substitute, particularly for the treatment and/or management of certain diseases
Szabo et al. The effect of muscle activity on the lymphatic and venous transport of lactate dehydrogenase
WO1996032134A3 (de) Konjugat aus einem wirkstoff, einem polyether und ggf. einem nicht als körperfremd angesehenen, nativen protein
RU2003118745A (ru) Заживляющее средство
EP0172326A1 (en) Compositions for the treatment of wounds
KR20000057371A (ko) 생체에 펩티드성 약물을 유입시키기 위한 국소 제제
CA2046598C (en) T-pa solubilisation
CN116889545B (zh) 一种重组人酸性成纤维细胞生长因子凝胶剂及其制备工艺
JP2938074B2 (ja) 表皮生長因子含有安定化組成物
JP2001213792A5 (ko)
WO1996032133A3 (de) Konjugat zur behandlung von entzündungs-, infektions- und/oder hauterkrankungen
EP0084157A2 (en) Cosmetics
CN108904449A (zh) 一种雾态软骨素在制备修复角膜的药物中的应用

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application